BetterLife provides update on neuroplastogenic activity of BETR-001

BetterLife (BETRF) Pharma recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. This phenomenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. The figure below shows images of rat brain cortical neurons in vitro treated with either BETR-001, or ketamine, or no drug. Only BETR-001 treatment was able to significantly induce formation of new spines in cultured neurons. In additional experiments, BETR-001 was also shown to significantly increase both the number and length of the neuronal dendrites. Based on its neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026.